Clinical Trial Update: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating adding KRT-232 (AMG 232) to standard chemotherapy in relapsed multiple myeloma, with plasmacytoma also listed; the study (NCT03031730) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasmacytoma

Drugs mentioned

• KRT-232 (AMG 232) (KRT-232)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Plasmacytoma, Recurrent Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2026-02-10